NBIX
Neurocrine Biosciences Inc
151.80$
+1.6%
vs. previous close
Closing price · As of: Sep 17, 2026
Ownership
Ownership Structure
Who owns Neurocrine Biosciences Inc (NBIX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 98.8% of the shares are freely tradable; institutional investors hold 103.9%.
Institutional ownership
?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
103.9%
Insiders
?Share of the stock held by the executives, founders and major shareholders of the company itself.
1.1%
Float
?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
98.8%
Short % of float
?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
6.5%
Shares Outstanding
?Total number of shares issued. Price times share count gives market cap.
102Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 13.17 | 13,385,607 | +4.3 | 03/31/2026 |
| Dodge & Cox | 5.49 | 5,584,707 | +2.3 | 06/30/2026 |
| JPMorgan Chase & Co | 5.35 | 5,442,067 | +4.6 | 03/31/2026 |
| AQR Capital Management LLC | 4.86 | 4,938,967 | +51.0 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 4.65 | 4,726,344 | +0.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.44 | 4,511,904 | +0.0 | 03/31/2026 |
| State Street Corp | 4.28 | 4,354,526 | +2.6 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Dodge & Cox Stock I | 3.90 | 3,964,000 | +0.0 | 06/30/2026 |
| iShares Core S&P Mid-Cap ETF | 3.46 | 3,521,341 | +0.0 | 08/31/2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.15 | 3,203,153 | +0.3 | 07/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Gorman Kevin Charles | Director | 517,797 | 78,601,585 $ | Sep 11, 2026 | direct |
| Gano Kyle | Chief Executive Officer | 154,728 | 23,487,710 $ | Sep 11, 2026 | direct |
| Benevich Eric | Chief Commercial Officer | 67,297 | 10,215,685 $ | Sep 11, 2026 | direct |
| Lippoldt Darin | Chief Legal Officer | 56,793 | 8,621,177 $ | Sep 11, 2026 | direct |
| Abernethy Matt | Chief Financial Officer | 42,808 | 6,498,254 $ | Sep 14, 2026 | direct |
| Cooke Julie | Chief Human Resources Officer | 24,025 | 3,646,995 $ | Sep 11, 2026 | direct |
| Onyia Jude | Chief Scientific Officer | 22,647 | 3,437,815 $ | Sep 11, 2026 | direct |
| Delaet Ingrid | Chief Regulatory Officer | 18,289 | 2,776,270 $ | Sep 11, 2026 | direct |
| Sherwin Stephen A | Director | 14,860 | 2,255,748 $ | Sep 2, 2026 | direct |
| Boyer David W. | Chief Corp. Affairs Officer | 8,722 | 1,324,000 $ | Sep 14, 2026 | direct |
| Keswani Sanjay Chandru | Chief Medical Officer | 3,281 | 498,056 $ | Sep 11, 2026 | direct |
| Norwalk Leslie V | Director | 2,430 | 368,874 $ | Jul 29, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | Boyer David W. | Chief Corp. Affairs Officer | Sell | 826 | 157.45 | 130,051 |
| Sep 14, 2026 | Abernethy Matt | Chief Financial Officer | Sell | 2,311 | 157.20 | 363,285 |
| Sep 11, 2026 | Delaet Ingrid | Chief Regulatory Officer | Other | 2,419 | 156.22 | 377,896 |
| Sep 11, 2026 | Delaet Ingrid | Chief Regulatory Officer | Other | 4,483 | 0.00 | – |
| Sep 11, 2026 | Boyer David W. | Chief Corp. Affairs Officer | Other | 1,936 | 156.22 | 302,442 |
| Sep 11, 2026 | Boyer David W. | Chief Corp. Affairs Officer | Other | 3,587 | 0.00 | – |
| Sep 11, 2026 | Onyia Jude | Chief Scientific Officer | Other | 1,936 | 156.22 | 302,442 |
| Sep 11, 2026 | Onyia Jude | Chief Scientific Officer | Other | 3,587 | 0.00 | – |
| Sep 11, 2026 | Keswani Sanjay Chandru | Chief Medical Officer | Other | 2,112 | 156.22 | 329,937 |
| Sep 11, 2026 | Keswani Sanjay Chandru | Chief Medical Officer | Other | 3,914 | 0.00 | – |
| Sep 11, 2026 | Cooke Julie | Chief Human Resources Officer | Other | 1,936 | 156.22 | 302,442 |
| Sep 11, 2026 | Cooke Julie | Chief Human Resources Officer | Other | 3,587 | 0.00 | – |
| Sep 11, 2026 | Abernethy Matt | Chief Financial Officer | Other | 2,709 | 156.22 | 423,200 |
| Sep 11, 2026 | Abernethy Matt | Chief Financial Officer | Other | 5,020 | 0.00 | – |
| Sep 11, 2026 | Benevich Eric | Chief Commercial Officer | Other | 3,386 | 156.22 | 528,961 |
| Sep 11, 2026 | Benevich Eric | Chief Commercial Officer | Other | 6,275 | 0.00 | – |
| Sep 11, 2026 | Gano Kyle | Chief Executive Officer | Other | 994 | 156.22 | 155,283 |
| Sep 11, 2026 | Gano Kyle | Chief Executive Officer | Other | 1,842 | 0.00 | – |
| Sep 11, 2026 | Gano Kyle | Chief Executive Officer | Other | 3,386 | 156.22 | 528,961 |
| Sep 11, 2026 | Gano Kyle | Chief Executive Officer | Other | 6,275 | 0.00 | – |
| Sep 11, 2026 | Lippoldt Darin | Chief Legal Officer | Other | 2,419 | 156.22 | 377,896 |
| Sep 11, 2026 | Lippoldt Darin | Chief Legal Officer | Other | 4,483 | 0.00 | – |
| Sep 11, 2026 | Gorman Kevin Charles | Director | Other | 7,839 | 156.22 | 1,224,609 |
| Sep 11, 2026 | Gorman Kevin Charles | Director | Other | 14,343 | 0.00 | – |
| Sep 9, 2026 | Benevich Eric | Chief Commercial Officer | Sell | 2,154 | 154.61 | 333,030 |
| Sep 9, 2026 | Benevich Eric | Chief Commercial Officer | Other | 3,194 | 43.24 | 138,109 |
| Sep 2, 2026 | Sherwin Stephen A | Director | Other | 1,000 | 0.00 | – |
| Aug 4, 2026 | Onyia Jude | Chief Scientific Officer | Other | 2,409 | 0.00 | – |
| Jul 29, 2026 | Norwalk Leslie V | Director | Other | 842 | 139.43 | 117,400 |
| Jul 28, 2026 | Norwalk Leslie V | Director | Sell | 1,250 | 182.01 | 227,508 |
| Jul 10, 2026 | Delaet Ingrid | Chief Regulatory Officer | Sell | 4,367 | 181.02 | 790,514 |
| Jul 10, 2026 | Delaet Ingrid | Chief Regulatory Officer | Other | 4,367 | 106.02 | 462,989 |
| Jul 9, 2026 | Lippoldt Darin | Chief Legal Officer | Sell | 10,000 | 179.60 | 1,796,014 |
| Jul 9, 2026 | Lippoldt Darin | Chief Legal Officer | Other | 10,000 | 81.49 | 814,900 |
| Jul 9, 2026 | Delaet Ingrid | Chief Regulatory Officer | Sell | 8,433 | 178.72 | 1,507,135 |
| Jul 9, 2026 | Delaet Ingrid | Chief Regulatory Officer | Other | 8,433 | 103.52 | 872,984 |
| Jul 8, 2026 | Delaet Ingrid | Chief Regulatory Officer | Sell | 2,737 | 178.54 | 488,672 |
| Jul 8, 2026 | Delaet Ingrid | Chief Regulatory Officer | Other | 2,737 | 103.52 | 283,334 |
| Jul 7, 2026 | Delaet Ingrid | Chief Regulatory Officer | Sell | 3,401 | 178.57 | 607,305 |
| Jul 7, 2026 | Delaet Ingrid | Chief Regulatory Officer | Other | 3,401 | 103.52 | 352,072 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.